Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2014; 4(8): 032-035


Prescription appetite suppressants: A drug utilisation study using a claims database

Ilse Truter.




Abstract

The primary aim of the study was to determine the prescribing and cost of prescription appetite suppressants in a defined private sector patient population. A retrospective drug utilisation study was conducted on a medical insurance claims database in South Africa for 2010 and 2011. In 2010, 37 patients (86.49% females) were prescribed 44 appetite suppressants at a cost of R9 813.39. The average age of patients was 40.95 (SD=12.37) years. In 2011, 27 patients (77.78% females) received 42 prescriptions for appetite suppressants at a cost of R9 967.73. The average age of patients was 40.04 years (SD=10.41). Most products were for phentermine (77.91%), followed by d-norpseudoephedrine (17.44%) and diethylpropion (2.33%). Prescribing patterns in 2010 and 2011 were relatively similar. In 2011, patients were prescribed a total of 630 products (all therapeutic classes). The most often other prescribed medicines in 2011 were gastrointestinal tract products (14.60%), cardiovascular agents (11.11%) and antimicrobial products (9.52%). The most frequently prescribed subclasses were HMG-CoA reductase inhibitors (statins), analgesic combinations, non-selective COX-inhibitors and selective serotonin re-uptake inhibitors. Appetite suppressants were not reimbursed by patientsÂ’ medical insurance benefits. A limited number of strictly regulated appetite suppressants were prescribed. Consumer studies that include over-the-counter appetite suppressants are recommended.

Key words: Appetite suppressants, Obesity, Drug utilization, Prescribing patterns






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.